# Kenneth S. Thress

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kenneth-s-thress/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,973 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 28 |
| i10-index | 36 |
| Last Known Institution | AstraZeneca (South Korea) |
| OpenAlex ID | https://openalex.org/A5040398168 |
| Works | 108 |

## Researcher papers

- [Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M](https://scholariq.org/papers/acquired-egfr-c797s-mutation-mediates-resistance-to-azd9291-in-non-small-cell/)
- [Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/association-between-plasma-genotyping-and-outcomes-of-treatment-with-osimertinib/)
- [Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity](https://scholariq.org/papers/preclinical-comparison-of-osimertinib-with-other-egfr-tkis-in-egfr-mutant-nsclc/)
- [Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib](https://scholariq.org/papers/assessment-of-resistance-mechanisms-and-clinical-implications-in-patients-with-i/)
- [Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-as-first-line-treatment-of-i-egfr-i-mutation-positive-advanced-non/)
- [EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291](https://scholariq.org/papers/egfr-mutation-detection-in-ctdna-from-nsclc-patient-plasma-a-cross-platform/)
- [Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation.](https://scholariq.org/papers/turnover-of-cyclin-e-by-the-ubiquitin-proteasome-pathway-is-regulated-by-cdk2/)
- [TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer](https://scholariq.org/papers/tatton-a-multi-arm-phase-ib-trial-of-osimertinib-combined-with-selumetinib/)
- [Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models](https://scholariq.org/papers/acquired-resistance-to-the-mutant-selective-egfr-inhibitor-azd9291-is-associated/)
- [Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses](https://scholariq.org/papers/gefitinib-plus-chemotherapy-versus-chemotherapy-in-epidermal-growth-factor/)
- [Abstract 4112: Overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquired resistance to osimertinib in T790M-positive NSCLC](https://scholariq.org/papers/abstract-4112-overgrowth-of-competing-resistance-mechanisms-such-as-an-acquired/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)

## Researcher university

- [AstraZeneca (South Korea)](https://scholariq.org/institutions/astrazeneca-south-korea/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.